Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial
- PMID: 32883555
- DOI: 10.1016/j.vaccine.2020.08.056
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial
Abstract
Background: This study evaluated the safety and immunogenicity of an investigational trivalent group B streptococcus (GBS) vaccine in US pregnant women, transplacental serotype-specific antibody transfer and persistence in infants, and serotype-specific antibodies in breast milk.
Methods: This randomized, observer-blind, placebo-controlled trial administered one dose of trivalent GBS vaccine (n = 49) or placebo (n = 26) to healthy pregnant 18-40-year-old women at 240/7-346/7 weeks' gestation. Women were enrolled from March 2014 to August 2015. Safety follow-up continued through postpartum day 180. Primary immunogenicity objectives were to evaluate serotype Ia/Ib/III-specific immunoglobulin G (IgG) levels in sera from women on day 1 (pre-vaccination), day 31, delivery and postpartum days 42 and 90, and from infants at birth (cord blood), days 42 and 90. Antibody transfer ratios (cord blood/maternal sera at delivery) and serotype-specific secretory immunoglobulin A (sIgA) and IgG in breast milk after delivery and on postpartum days 42 and 90 were evaluated. The planned sample size was not based on statistical assumptions for this descriptive study.
Results: Baseline characteristics were similar between groups. Serious adverse events were reported for 16% of GBS-vaccinated women and 15% of their infants, and 15% of placebo recipients and 12% of their infants; none were fatal or deemed vaccine-related. Serotype-specific IgG geometric mean concentrations (GMCs) were 13-23-fold higher in vaccine vs placebo recipients on day 31 and persisted until postpartum day 90. Median antibody concentrations were substantially higher in women with detectable pre-vaccination antibody concentrations. Antibody transfer ratios in the vaccine group were 0.62-0.82. Infant IgG GMCs and breast milk sIgA GMCs were higher in the vaccine vs the placebo group at all timepoints.
Conclusions: Maternal immunization with the trivalent GBS vaccine in US women had a favorable safety profile, elicited antibodies that were transplacentally transferred and persisted in infants for a minimum of 3 months.
Clinical trial registration: Clinicaltrials.gov, NCT02046148.
Keywords: Breast milk sIgA; Group B streptococcus; Immunogenicity; Maternal immunization; Safety.
Copyright © 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Z Bebia, M Lattanzi, O Henry, A Karsten, I Margarit, G Buffi and L Grassano are employees of the GSK group of companies. M Lattanzi, O Henry, A Karsten and I Margarit hold shares in the GSK group of companies. A Dreisbach was an employee of the GSK group of companies. GK Swamy, KM Edwards and JD Campbell report funding from the GSK group of companies for the work under consideration. TD Metz reports that her institution received funding from the GSK group of companies for the work under consideration. Outside the submitted work, GK Swamy is an advisor and chair of IDMCs for the GSK group of companies for RSV vaccine trials in pregnant women and chair of IDMCs for Pfizer for GBS vaccine trials in pregnant and nonpregnant women. Outside the submitted work, KM Edwards is an advisor to Bionet, X4 Pharmaceuticals, Merck, and IBM, and is on DSMBs for Moderna, Roche, Sanofi Pasteur and Sequiras. KM Edwards also reports grants from the CDC and the NIH. RH Beigi and DE Soper report no potential conflicts.
Similar articles
-
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.Lancet Infect Dis. 2016 Aug;16(8):923-34. doi: 10.1016/S1473-3099(16)00152-3. Epub 2016 Apr 29. Lancet Infect Dis. 2016. PMID: 27139805 Clinical Trial.
-
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.Vaccine. 2020 Apr 3;38(16):3227-3234. doi: 10.1016/j.vaccine.2020.02.085. Epub 2020 Mar 10. Vaccine. 2020. PMID: 32169390 Clinical Trial.
-
Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.Clin Infect Dis. 2020 Jun 10;70(12):2570-2579. doi: 10.1093/cid/ciz737. Clin Infect Dis. 2020. PMID: 31394574 Free PMC article. Clinical Trial.
-
Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.Vaccine. 2013 Aug 28;31 Suppl 4:D52-7. doi: 10.1016/j.vaccine.2013.02.029. Vaccine. 2013. PMID: 23973347 Review.
-
The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review.Vaccine. 2024 Jan 12;42(2):84-98. doi: 10.1016/j.vaccine.2023.11.056. Epub 2023 Dec 9. Vaccine. 2024. PMID: 38072754 Review.
Cited by
-
Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study.Infection. 2024 Sep 8. doi: 10.1007/s15010-024-02380-0. Online ahead of print. Infection. 2024. PMID: 39244714
-
Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions.Pathogens. 2024 Feb 23;13(3):200. doi: 10.3390/pathogens13030200. Pathogens. 2024. PMID: 38535543 Free PMC article. Review.
-
An Overview of Antibiotic Therapy for Early- and Late-Onset Neonatal Sepsis: Current Strategies and Future Prospects.Antibiotics (Basel). 2024 Mar 10;13(3):250. doi: 10.3390/antibiotics13030250. Antibiotics (Basel). 2024. PMID: 38534685 Free PMC article. Review.
-
Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.Vaccine X. 2024 Feb 23;18:100464. doi: 10.1016/j.jvacx.2024.100464. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38495929 Free PMC article. Review.
-
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant.Med Sci Monit. 2024 Jan 17;30:e942799. doi: 10.12659/MSM.942799. Med Sci Monit. 2024. PMID: 38229424 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical